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etter to the Editorerspectives on the production of pluripotent cells
out using this technology in order to determine its poten-rom hematopoietic cells
ear Editor,
he myth of Prometheus appeared in the writings of Hes-
od, a Greek epic poet, who lived at the end of the VIII
entury BC. According to the myth, Prometheus received a
unishment from Zeus, which should last eternally, as he
as immortal. Unbreakable chains, forged byHephaestus, fas-
ened Prometheus to a rock inCaucasus andan imposing eagle
ould come to eat his liver every day. During the dark night,
or which Prometheus longed, the eaten organ would grow
ack again so that it could be devoured by the bird of prey the
ery next day. Some tell that the Greek hero Heracles (Roman
ercules) freed Prometheus years later.
It is interesting that tissue regeneration was already men-
ioned in VIII century BC folklore, in a way that stories showed
nterest in a possibility that was not yet imagined in the med-
cal science of the era.
The advances in the state of the art related to regeneration
ave come to a point where scientists are attempting to fully
nderstand the mechanisms and to master techniques of cell
eprogramming in order to develop regenerative medicine.
Discussions on the reprogramming of cells started more
han 50 years ago1 and until now questions about which
echanisms are involved remain inadequately answered as
o questions on the real applications and safety of the tech-
ique. Attempts to revert the lineage commitment of certain
nimal cells date back to 1960 when Gurdon obtained cells
ith characteristics of different stages of embryonic develop-
ent by transferring of nuclei of endodermal cells of Xenopus
aevis to enucleated oocytes. This shows the importance of
uclear modiﬁcations during embryonic development.2 In
962, Gurdon managed to reprogram completely differen-
iated cells (enterocytes) using these procedures.3 In 2006,
akahashi and Yamanaka4 successfully determined the genes
hat are related to maintenance of the pluripotent state of a
ell. They discovered, by introducing 24 transcription factor
enes using retroviral vectors that only four were necessary
o reprogram ﬁbroblasts to cells with features found in embry-
nic stem cells; this lineage was named induced pluripotent
tem cells (iPSC).4 These cells were seen as the great step
orward in regenerative medicine despite of the low efﬁ-
iency of the technique, the lack of safety of iPSC due to
he possibility of teratogenesis when introduced into a livingorganism and due to the fact that retroviruses were neces-
sary to accomplish cell reprogramming. The Medicine and
Physiology Nobel Prize of 2012 was awarded to Gurdon,2 and
to Takahashi and Yamanaka,4 putting cell reprogramming
back in the avant-garde of science.5 The understanding of the
underlying mechanisms by which cell reprogramming occur,
as described by Yamanaka and Takahashi4 in 2006, allowed
the use iPSCs for hematologic purposes to be considered. In
2009, the ﬁrst lineage of hematopoietic progenitor cells (CD34+
and CD43+) was established from iPSCs as well as colony
forming units of granulocytes, erythrocytes, macrophages and
megakaryocytes (CFU-GEMM), symbolizing the possibility of
future applications of cell reprogramming in the treatment
of hematological diseases.6 However the use of these cells
was still limited due to several reasons which impeded the
development of other iPSCs-based cell therapies including ter-
atogenesis, safety issues regarding the use of retroviruses and
the low efﬁciency of the method.
In spite of the advances made towards understanding cell
reprogramming mechanisms and the ever-growing efforts to
manage technical issues, little progress had been made until
recently when the possibility of triggering the conversion of
somatic cells to pluripotent cells by applying extreme exter-
nal stimulation was reported.7 The cells obtained in these
experiments were named Stimulus-triggered Acquisition of
Pluripotency (STAP) cells. In this recent work, pluripotency
was acquired from hematopoietic system cells when CD 45+
lymphocytes were exposed to an acidic environment (pH 5.7).
The results are encouraging and the STAP cells have been
shown to be similar to iPSCs in potency and gene expres-
sion with this reprogramming method being more efﬁcient
and free of the risks inherent to the use of retroviruses. How-
ever, STAP cells also display the capacity of forming teratomas,
an undesirable feature that limits their use in therapy for
the time being. Nevertheless, the increase in efﬁciency and
drastically diminished costs, suggest that these cells can be
produced in a large scale for future in-depth studies that
may culminate in the establishment of cell lineages that
make cell therapy feasible. Further studies must be carriedtial and limitations. Can we expect STAP cells to be used to
generate in vitro hematopoietic progenitor cells in the near
future?
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